The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease

Benjamin E Onderdonk; Stanley I Gutiontov; Steven J Chmura

doi:10.1016/j.hoc.2019.09.003

The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease

Hematol Oncol Clin North Am. 2020 Feb;34(1):307-320. doi: 10.1016/j.hoc.2019.09.003. Epub 2019 Oct 28.

Authors

Benjamin E Onderdonk¹, Stanley I Gutiontov¹, Steven J Chmura²

Affiliations

¹ Department of Radiation and Cellular Oncology, University of Chicago, 5758 S Maryland Avenue, Chicago, IL 60637, USA.
² Department of Radiation and Cellular Oncology, University of Chicago, 5758 S Maryland Avenue, Chicago, IL 60637, USA. Electronic address: schmura@radonc.uchicago.edu.

PMID: 31739951
DOI: 10.1016/j.hoc.2019.09.003

Abstract

This review outlines the history of the oligometastatic state from its first proposal to the current formulation. The article discusses the accumulating evidence for the biology of oligometastases, including clinical parameters, such as number and rate of progression, as well as ongoing molecular profiling efforts. The authors then discuss the current state of prospective clinical trials. They review the early site-specific as well as subsite agnostic studies using stereotactic body radiation therapy. Moreover, the article makes the case for why phase II trials should not be practice changing, and highlights the pivotal importance of accruing to phase III clinical trials.

Keywords: Immunotherapy; Oligometastases; Radiation; SABR; SBRT; Stereotactic body radiotherapy.

Publication types

Review

MeSH terms

Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Humans
Neoplasm Metastasis
Neoplasms / pathology
Neoplasms / radiotherapy*
Radiosurgery* / methods
Radiosurgery* / trends